Iambic Therapeutics Inc. (IAM)

Currency in USD
14.93
+1.55(+11.55%)
Real-time Data·
IAM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
12.8015.00
52 wk Range
9.6025.00
Key Statistics
Prev. Close
13.38
Open
13.84
Day's Range
12.8-15
52 wk Range
9.6-25
Volume
708.19K
Average Volume (3m)
854.47K
1-Year Change
-
Book Value / Share
NA
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IAM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
24.67
Upside
+65.22%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with high price volatility

Iambic Therapeutics Inc. News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 24.67
(+65.22% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jefferies
Buy35.00+133.80%-New CoverageNov 10, 2026

Earnings

Latest Release
Sep 21, 2026
EPS / Forecast
-2,24 / --
Revenue / Forecast
12,75M / --
EPS Revisions
Last 90 days

IAM Income Statement

Compare IAM to Peers and Sector

Metrics to compare
IAM
Peers
Sector
Relationship
P/E Ratio
−6.7x−2.1x−0.2x
PEG Ratio
-−0.060.00
Price/Book
−2.7x1.0x2.6x
Price / LTM Sales
34.8x64.2x2.8x
Upside (Analyst Target)
68.0%185.1%60.9%
Fair Value Upside
Unlock10.4%9.5%Unlock

Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics. Iambic Therapeutics, Inc. was formerly known as Entos, Inc. and changed its name to Iambic Therapeutics, Inc. in May 2023. The company was incorporated in 2019 and is based in San Diego, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1,38M2,91%18,45M
Other Institutional Investors
57,74M97,09%772,53M
Public Companies & Retail Investors
0,000,00%0,00
Total
59,12M100,00%790,97M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Qatar Holding LLC20,71%9 817 255131 355
NVIDIA Corporation20,28%9 611 286128 599

FAQ

What Is the Iambic Therapeutics (IAM) Stock Price Today?

The Iambic Therapeutics stock price today is 14,93 USD.

What Stock Exchange Does Iambic Therapeutics Trade On?

Iambic Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Iambic Therapeutics?

The stock symbol for Iambic Therapeutics is "IAM."

What Is the Iambic Therapeutics Market Cap?

As of today, Iambic Therapeutics market cap is 634,22M USD.

What Is Iambic Therapeutics's Earnings Per Share (TTM)?

The Iambic Therapeutics EPS (TTM) is -4,27.

From a Technical Analysis Perspective, Is IAM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Iambic Therapeutics Stock Split?

Iambic Therapeutics has split 0 times.

How Many Employees Does Iambic Therapeutics Have?

Iambic Therapeutics has 171 employees.

What is the current trading status of Iambic Therapeutics (IAM)?

As of Nov 10, 2026, Iambic Therapeutics (IAM) is trading at a price of 14,93 USD, with a previous close of 13,38 USD. The stock has fluctuated within a day range of 12,80 USD to 15,00 USD, while its 52-week range spans from 9,60 USD to 25,00 USD.

What Is Iambic Therapeutics (IAM) Price Target According to Analysts?

The average 12-month price target for Iambic Therapeutics is 24,67 USD, with a high estimate of 30 USD and a low estimate of 22 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +65,22% Upside potential.

What Is the IAM Premarket Price?

IAM's last pre-market stock price is 13,80 USD. The pre-market share volume is 28 690,00, and the stock has decreased by 0,42, or 3,14%.

What Is the IAM After Hours Price?

IAM's last after hours stock price is 14,63 USD, the stock has decreased by 1,25, or 9,34%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.